Alzet model 1003d

Manufactured by Durect

Sourced in United States

The Alzet model 1003D is a laboratory equipment designed for the continuous and controlled delivery of substances to small laboratory animals. It is a type of osmotic pump that utilizes the osmotic gradient to deliver a pre-determined amount of a substance over a specified duration of time.

Automatically generated - may contain errors

Lab products found in correlation

Vetbond, by 3M (1 mentions) Alzet brain infusion kit 3, by Durect (1 mentions) Taxol, by Bristol-Myers Squibb (1 mentions)

Close spelling variants of this product

ALZET #1003D (2 citations) Alzet Model 1003D/3day delivery (2 citations) ALZET osmotic minipump model 1003D (2 citations)

5 protocols using alzet model 1003d

Continuous Epidural Delivery of XPro1595 Post-SCI

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immediately after surgery, mice were implanted with micro-osmotic pumps (Alzet model 1003D, Durect Corporation, Cupertino, CA, USA), which, for a period of three days, continuously epidurally delivered XPro1595 (2.5 ng/mL/1 μL/h, INmune Bio Inc., Monrovia, CA, USA) or saline (0.9% physiological saline/1 μL/h), as previously described [26 (link)]. The pumps were placed in such a way that the delivering end of the catheter (Micro-Renathane Tubing MRE-040, AgnTho’s AB, Lindingö, Sweden) was on top of the injured spinal cord. The catheter was sutured to the musculature, and the suture and placement of it were secured using Vetbond (3M Animal Care Products, St. Paul, MN, USA). The pump was installed in a subcutaneous pocket on the lateral back of the mouse and kept in situ throughout the entire experiment.
Mice were allowed to survive 0 h (naïve, n = 10), 1 h (n = 5/treatment group), 3 h (n = 3), 1 day (n = 15/treatment group), 3 days (n = 15/treatment group), 7 days (n = 15/treatment group), 14 days (n = 10/treatment group), 21 days (n = 13/treatment group), 24 days (n = 3/treatment group), 28 days (n = 12/treatment group), or 35-days (n = 12/treatment group) after SCI. Saline-treated mice with 3 h survival are also part of another study on inflammatory markers in SCI [6 (link)].

Lund M.C., Ellman D.G., Nielsen P.V., Raffaele S., Fumagalli M., Guzman R., Degn M., Brambilla R., Meyer M., Clausen B.H, & Lambertsen K.L. (2023). Selective Inhibition of Soluble Tumor Necrosis Factor Alters the Neuroinflammatory Response following Moderate Spinal Cord Injury in Mice. Biology, 12(6), 845.

+ Open protocol

+ Expand

Temozolomide Delivery via Osmotic Pumps

Check if the same lab product or an alternative is used in the 5 most similar protocols

The chemotherapeutic agent temozolomide (TMZ), Temodal® 2.5 mg/ml (Merck Sharp & Dohme, Sweden) was used for the in vivo experiments. The powder was dissolved in sterile PBS (GIBCO-Life technologies) according to the manufacturer’s protocol and adjusted to the desired concentration. 3-day mini-osmotic pumps Alzet® model 1003D, fill volume 100 μl, pumping rate 1 μl/h (DURECT Corporation) were used for CED-TMZ. TMZ solution concentration was 2.5 mg/ml which corresponds to the dose of 2.4 mg/Kg/day in a mouse weighing 25 g. The total administered dose is 180 μg in 3 days. The mini-osmotic pumps were filled with 100 μl of solutions containing TMZ and coupled to the Alzet® brain infusion kit 3 (DURECT Corporation) with a 2 cm catheter tube according to the manufacturer’s protocol. The pumps assemblies were incubated at 37 °C overnight in sterile PBS (GIBCO-Life technologies) before use.

Enríquez Pérez J., Kopecky J., Visse E., Darabi A, & Siesjö P. (2020). Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas. BMC Cancer, 20, 7.

+ Open protocol

+ Expand

Intracisternal Infusion of IFN-γ and FC in Rats

Check if the same lab product or an alternative is used in the 5 most similar protocols

IFN-γ, FC, and FC with IFN-γ were administered to naïve rats, and IFN-γ antagonist was administered to the IONI group intracisternally as previously described.^{32 (link)} Briefly, rats were anesthetized, as described above, and placed in a stereotaxic frame. A small hole was drilled into the most caudal part of the occipital bone to insert a polyethylene tube (0.8 mm diameter, Natsume, Tokyo, Japan). The tip of the tube was placed at a depth of 4 mm in the cisterna magna, and the tube was fixed to the skull. The other tip of the tube was connected to an osmotic mini pump (Figure 1). The total volume of the pump was 100 μL; moreover, it was used to inject drugs at a rate of 1 μL/h for 3 days (Alzet model 1003D, Durect, Cupertino, CA, USA). The tube connected to the pump was implanted subcutaneously on the back. The pump and tube were filled with IFN-γ (10 ng/100 μL), FC (100 fmol/100 μL), IFN-γ mixed with FC, or vehicle (PBS); or IFN-γ antagonist (0.5 mg/500 μL) or vehicle (acetic acid).Figure 1.

Intracisternal catheter fixed to the occipital bone. The catheter is connected to an osmotic mini pump and drug was administered into the cisterna magna.

Asano S., Okada-Ogawa A., Kobayashi M., Yonemoto M., Hojo Y., Shibuta I., Noma N., Iwata K., Hitomi S, & Shinoda M. (2023). Involvement of interferon gamma signaling in spinal trigeminal caudal subnucleus astrocyte in orofacial neuropathic pain in rats with infraorbital nerve injury. Molecular Pain, 19, 17448069231222403.

+ Open protocol

+ Expand

Brain Distribution of Tesevatinib after Intraperitoneal Infusion

Check if the same lab product or an alternative is used in the 5 most similar protocols

The brain distribution of tesevatinib after intraperitoneal infusion at a constant rate was also investigated in WT and TKO mice (n=4 per group). A drug-loaded osmotic mini pump (ALZET, model 1003D, Durect Corporation, Cupertino, CA) was surgically implanted into the intraperitoneal cavity to administer tesevatinib (10 mg/mL in DMSO) at a constant infusion rate of 1 μL/hr as previously described (20 ). Animals were euthanized 48 hours after intraperitoneal implantation. Plasma and brain were harvested, flash frozen and stored at −80°C until analysis.

Kizilbash S.H., Gupta S.K., Parrish K.E., Laramy J.K., Kim M., Gampa G., Carlson B.L., Bakken K.K., Mladek A.C., Schroeder M.A., Decker P.A., Elmquist W.F, & Sarkaria J.N. (2021). In vivo efficacy of tesevatinib in patient-derived xenograft glioblastoma models may be limited by tissue binding and compensatory signaling. Molecular cancer therapeutics, 20(6), 1009-1018.

+ Open protocol

+ Expand

Transplacental Pharmacokinetics of Paclitaxel and Digoxin

Check if the same lab product or an alternative is used in the 5 most similar protocols

Paclitaxel or digoxin was continuously administered to pregnant Mdr1a/b^−/− or WT mice from GD13.5 and 15.5 for 48 h (paclitaxel) or from GD12.5 and 14.5 for 72 h (digoxin) using an osmotic pump (Alzet model 1003D: Durect, Cupertino, CA, USA) with a pumping rate of 1.0 μL/h. Osmotic pumps were filled with paclitaxel (Taxol®, Bristol Myers Squibb) diluted to 3.51 mM with water or digoxin (230 μM) dissolved in 80% PEG400/DMSO and implanted into the subcutaneous tissue of the backs of mice under deep anesthesia with isoflurane. Maternal blood was collected from a tail vein in studies to determine the maternal plasma concentration during the continuous administration. At 48 or 72 h after starting administration, the fetuses were decapitated for collection of fetal blood with a heparinized microhematocrit capillary tube. The maternal blood was collected from the left jugular vein, and then the cerebrum of the mother was excised and weighed.

Fujita A., Noguchi S., Hamada R., Inoue S., Shimada T., Katakura S., Maruyama T., Sai Y., Nishimura T, & Tomi M. (2022). Limited Impact of Murine Placental MDR1 on Fetal Exposure of Certain Drugs Explained by Bypass Transfer Between Adjacent Syncytiotrophoblast Layers. Pharmaceutical Research, 39(7), 1645-1658.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!